Home Molecular Testing Methods Single-Gene Sequencing Test: DNA Variants, Diagnosis, and Results

Single-Gene Sequencing Test: DNA Variants, Diagnosis, and Results

By
Vita Library
-
4
Single-gene sequencing searches one selected gene for DNA variants. Learn when focused testing is useful, what results mean, what may be missed, and next steps.

A single-gene sequencing test looks for disease-related DNA variants in one selected gene. It is most useful when a person’s symptoms, biochemical findings, imaging, or family history point strongly to a specific genetic condition. By concentrating on one gene, the laboratory can often provide detailed coverage and focused interpretation without generating the large number of unrelated or uncertain findings that may accompany broader testing.

“Single-gene test” does not describe one universal laboratory method. One assay may sequence only coding exons, while another also examines splice boundaries, selected intronic regions, and deletions or duplications. Some laboratories use Sanger sequencing; others use next-generation sequencing, long-range PCR, or a combination of methods. Before testing, patients and clinicians should confirm which regions and variant types are included. A negative result can be informative, but it does not exclude changes outside the assay’s scope or a diagnosis caused by another gene.

  • Single-gene sequencing is designed for a specific, well-supported diagnostic question.
  • The test may use Sanger or next-generation sequencing and may or may not include deletion/duplication analysis.
  • Results are interpreted according to variant evidence, inheritance, and the patient’s clinical features.
  • A pathogenic variant can confirm a diagnosis, identify carrier status, or clarify risk for relatives.
  • The meaning of a negative result depends on how well the selected gene fits the condition and how comprehensively it was tested.

Table of Contents

Why a Single Gene May Be the Right Test

Genetic disorders can be approached narrowly or broadly. A narrow approach is appropriate when the evidence already identifies one gene as the most likely cause. A broad panel, exome, or genome test is more useful when many genes can produce the same findings or when the clinical pattern is unclear.

A single-gene test may be chosen when:

  • the condition has a distinctive clinical appearance linked mainly to one gene;
  • a biochemical or enzyme test points to a specific molecular pathway;
  • pathology or imaging has a highly characteristic pattern;
  • a close relative has a pathogenic variant in that gene;
  • an earlier screening test identified a candidate variant that needs diagnostic confirmation;
  • a treatment decision depends on variants in one particular gene;
  • the gene contains technically difficult regions that benefit from a specialized assay.

The strongest reason to test one gene is a high pretest probability. This means that, before the DNA result is known, the clinical evidence already makes that gene a convincing explanation. In this setting, focused testing can be faster to interpret and may reduce the chance of unrelated findings.

Single-gene testing is not automatically simpler. Some genes are very large, have many exons, contain repeat sequences, or have highly similar pseudogenes. Others are affected by several variant mechanisms, including sequence changes, deletions, duplications, repeat expansions, methylation abnormalities, or structural rearrangements. A complete diagnostic strategy may therefore require more than ordinary sequencing.

The term can also refer to two different scopes:

  • Full-gene sequencing: The laboratory examines most or all coding exons and usually nearby splice boundaries.
  • Targeted variant testing: The laboratory tests one known change, such as a familial pathogenic variant or a common founder variant.

Targeted testing is less comprehensive but is usually sufficient when the exact family variant is documented. Full-gene testing is used when the gene is known but the specific change is not.

A focused test may avoid secondary findings—medically important variants unrelated to the original reason for testing—that can arise with exome or genome sequencing. It may also produce fewer variants of uncertain significance because only one gene is reviewed. However, choosing the wrong gene can delay diagnosis. Careful clinical evaluation before ordering is therefore as important as the laboratory technology.

What the Laboratory Actually Examines

The phrase “single-gene sequencing” can conceal important differences in coverage. The requisition, test description, and final report should identify the transcript, regions, and alteration types assessed.

Coding exons

Most tests focus on exons that contribute to the protein-coding transcript. Disease-causing missense, nonsense, frameshift, and canonical splice-site variants often occur in these regions. Laboratories may choose one clinically relevant transcript when a gene has several isoforms. A variant’s numbering can differ between transcripts, so the report should include a transcript accession and version.

Exon-intron boundaries

Sequencing commonly extends a short distance into the introns beside each exon. This allows detection of variants that disrupt normal splicing. The extension may be 10, 20, or more bases, but there is no universal boundary. Deep intronic variants can be pathogenic and will not be detected unless specifically included.

Untranslated and regulatory regions

Some assays include 5′ or 3′ untranslated regions, promoters, or other regulatory segments when established disease-causing variants occur there. Many do not. A laboratory should not imply that the entire gene locus has been examined when only coding regions were sequenced.

Deletions and duplications

Sequencing is optimized to read bases, not always to count gene copies. A whole-exon deletion or duplication may require a separate method, such as multiplex ligation-dependent probe amplification, quantitative PCR, read-depth analysis, or chromosomal microarray. Some single-gene products bundle sequencing and deletion/duplication analysis; others list them as separate orders.

This distinction matters for conditions in which copy-number variants account for a substantial share of diagnoses. A “negative sequencing result” may leave a major part of the gene’s variant spectrum untested.

Specialized variant types

A gene may require an assay designed for its biology. Examples include:

  • repeat-primed PCR for repeat expansions;
  • methylation-sensitive testing for imprinting disorders;
  • long-range PCR to separate a gene from its pseudogene;
  • RNA analysis to demonstrate abnormal splicing;
  • Southern blot or long-read sequencing for large or complex changes;
  • mitochondrial testing with a validated heteroplasmy threshold.

Testing only by standard sequencing can be inadequate if the suspected disorder is commonly caused by one of these mechanisms.

Laboratory platforms

A focused assay may use Sanger sequencing, targeted next-generation sequencing, or both. Sanger reads individual PCR products and is effective for modest regions. NGS can cover a larger gene more efficiently and at greater depth. Neither platform guarantees complete detection; assay design and validation are more important than the platform name.

For genes with pseudogenes or repeated segments, laboratories may first perform gene-specific long-range amplification and then sequence the resulting product. This prevents reads from being assigned to the wrong genomic location. Patients should look for a test specifically validated for the gene rather than assuming any generic sequencing assay is equivalent.

How Phenotype and Inheritance Guide Testing

A DNA variant becomes clinically meaningful only when it is evaluated within a gene-disease relationship and an inheritance pattern. The same laboratory finding can have different implications depending on why the test was ordered.

Matching the phenotype

Phenotype means the person’s observable clinical features: symptoms, age of onset, examination findings, laboratory values, imaging, and disease course. A strong match between phenotype and the known effects of a gene increases the likelihood that a detected pathogenic variant explains the condition.

Testing can be less informative when the phenotype is broad or nonspecific. Developmental delay, neuropathy, epilepsy, cardiomyopathy, hearing loss, and immune dysfunction can each be caused by many genes. A single-gene choice may still be reasonable if a distinctive feature narrows the diagnosis, but a multigene strategy is often more efficient.

Providing detailed clinical information helps the laboratory interpret variants. Terms such as “weakness” or “kidney disease” are less useful than specific findings, age at onset, affected organ systems, and key negative observations. Standardized phenotype terms can improve the match between the patient and published cases.

Autosomal dominant inheritance

In a dominant condition, one pathogenic variant in one copy of the gene may be sufficient. The variant may be inherited from an affected parent or occur de novo in the child. Some dominant conditions show reduced penetrance, meaning not everyone with the variant develops recognizable disease. Others show variable expressivity, meaning severity differs among relatives.

A negative parental test supports de novo occurrence in blood but does not completely exclude low-level parental germline mosaicism. Recurrence risk may therefore be greater than zero even when neither parent has the variant on routine testing.

Autosomal recessive inheritance

A recessive diagnosis generally requires pathogenic variants in both gene copies. The variants should usually be in trans—one inherited from each parent. If two variants are found but their phase is unknown, testing parents can determine whether they are on opposite chromosomes.

Finding only one pathogenic variant does not usually confirm a recessive disorder. A second change may be outside the sequenced regions, may be a deletion or duplication, or may be in another gene. Alternatively, the person may simply be a carrier and have symptoms for a different reason.

X-linked and mitochondrial inheritance

For X-linked genes, interpretation depends on the person’s sex-chromosome complement, the disease mechanism, and X-inactivation. A hemizygous pathogenic variant may cause disease in a person with one X chromosome, while a heterozygous person may be unaffected or may have variable symptoms.

Mitochondrial variants can be present at different proportions in different tissues, called heteroplasmy. A blood result may not reflect the level in muscle, urine, or another affected tissue. Not all tests labeled single-gene sequencing are validated for mitochondrial DNA or low-level heteroplasmy.

Somatic versus germline testing

A variant found in a tumor can be somatic, meaning limited to cancer cells, or germline, meaning present throughout the body and potentially inherited. Tumor-only single-gene testing cannot always distinguish the two. When a result suggests an inherited cancer syndrome, confirmation in blood, saliva, or another normal specimen may be recommended.

Understanding Positive and Uncertain Results

The report should provide the gene, transcript, DNA change, protein change when applicable, zygosity, and classification. Laboratories generally classify variants as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign.

Pathogenic and likely pathogenic findings

A pathogenic result has strong evidence that the variant causes disease. A likely pathogenic result has substantial but not complete evidence. These categories are usually considered clinically actionable when the variant and inheritance pattern fit the patient.

Evidence can include:

  • previous reports in people with the same condition;
  • absence or extreme rarity in large population databases;
  • a predicted loss-of-function effect in a gene where that mechanism causes disease;
  • functional studies showing an abnormal protein or RNA effect;
  • segregation with disease in multiple relatives;
  • occurrence as a confirmed de novo variant;
  • location in a well-established critical domain or mutational hotspot.

A positive molecular diagnosis can end a diagnostic search, guide surveillance, identify treatments or trials, prevent unnecessary procedures, and provide information for relatives. Its effect on care varies. Some conditions have gene-specific therapies, while others have no disease-modifying treatment but benefit from anticipatory monitoring and accurate counseling.

A result does not erase clinical uncertainty. Some genes cause a spectrum of disease, and the exact variant may not predict severity. A person can also have more than one diagnosis. Clinicians should continue evaluating findings not explained by the result.

Carrier findings

For an autosomal recessive condition, one pathogenic variant usually indicates carrier status rather than a diagnosis. The report may recommend testing the reproductive partner if the condition is severe or relatively common in the relevant population. If both partners carry pathogenic variants in the same gene, each pregnancy typically has a 25% chance of being affected, although special situations can alter this calculation.

Variants of uncertain significance

A variant of uncertain significance is not a positive result. It means available evidence cannot establish whether the change disrupts gene function or contributes to disease. A VUS should generally not be used alone for predictive testing, major surgery, or other irreversible decisions.

The clinical team may ask whether the variant fits the phenotype, whether affected relatives carry it, and whether RNA or functional studies are available. Family testing is most useful when the laboratory or genetics professional has a defined plan for how the result could change classification. Testing many healthy relatives without that plan can create more confusion.

Variant classifications can change. Laboratories may periodically review evidence or accept a reinterpretation request. The ordering clinician should ensure that contact details remain current and that the patient understands how amended reports are communicated.

Benign and likely benign findings

Benign variants are not considered causes of the disorder. Many are common differences among people. They may be omitted from the report. A benign result at one position does not mean that the entire gene is normal; it refers only to that variant.

What a Negative Result Does and Does Not Mean

A negative single-gene test means the laboratory did not identify a reportable variant within the regions and alteration types it evaluated. It is not equivalent to proving that the gene has no relevant abnormality.

The result may be truly negative because the person does not have a disorder caused by that gene. Other explanations include:

  • the causal change lies in an untested intron, promoter, or regulatory element;
  • the disorder is caused by a deletion, duplication, repeat, methylation change, or rearrangement not assessed;
  • the relevant gene copy failed to amplify;
  • mosaicism is below the assay’s detection limit or absent from the submitted tissue;
  • scientific knowledge has not yet linked the variant or region to disease;
  • a different gene causes the same clinical picture;
  • the condition is multifactorial, acquired, or nongenetic.

The post-test probability depends on test sensitivity and the strength of the original diagnosis. Suppose a condition has a highly characteristic biochemical marker and nearly all affected people have detectable variants in one gene. A negative comprehensive test may still leave a meaningful chance of an unusual variant and justify specialized follow-up. In contrast, if the initial gene choice was based on nonspecific symptoms, the result may simply signal that a broader approach is needed.

Read the limitations section carefully. It should state whether deletion/duplication analysis was included, how far intronic coverage extends, whether difficult exons were excluded, and whether mosaicism can be detected. “No pathogenic variant identified” is a statement about the assay, not the entire genome.

A negative result can still be useful. It may reduce the likelihood of a diagnosis, prevent unnecessary condition-specific surveillance, or redirect testing. It can also help distinguish a clinical mimic when combined with biochemical or imaging evidence. The result should be discussed with the clinician who selected the test, because that person can judge whether the original suspicion remains strong.

Family Testing, Reproductive Choices, and Care

A confirmed pathogenic variant can provide information beyond the individual tested. The pattern of inheritance determines which relatives may be at risk and which test is appropriate.

For dominant disorders, parents, siblings, and adult children may each have a meaningful chance of carrying the variant. Predictive testing should usually be offered with counseling, especially when disease onset is later in life or preventive options are limited. Testing children for adult-onset conditions requires particular ethical consideration and is generally reserved for situations in which childhood management would change.

For recessive disorders, parents are usually carriers, and siblings may be affected, carriers, or neither. Once both familial variants are known, relatives can have targeted testing. Reproductive options may include natural conception with prenatal diagnosis, preimplantation genetic testing, donor gametes, adoption, or choosing not to test. These are personal decisions, and counseling should be nondirective.

When a variant appears de novo, parental testing can refine recurrence risk. A negative blood test in both parents makes recurrence less likely but cannot rule out germline mosaicism. If a parent is mosaic, the chance of transmission depends on whether reproductive cells carry the variant and cannot always be calculated precisely.

A genetic diagnosis can change medical care in several ways:

  • initiating organ-specific screening before symptoms appear;
  • avoiding medications or procedures known to be risky in the condition;
  • choosing a targeted treatment or clinical trial;
  • informing anesthesia, pregnancy, or surgical planning;
  • connecting the family with a specialty clinic or patient organization;
  • ending repeated diagnostic procedures that are unlikely to help.

The same variant may not produce identical outcomes in every relative. Medical recommendations should be based on each person’s age, symptoms, comorbidities, and current professional guidance, not only carrier status.

Privacy and discrimination concerns also matter. Laws and protections vary by country and may not apply equally to health, life, disability, or long-term-care insurance. Patients can discuss these issues before testing, especially when results could reveal risk in healthy relatives.

Choosing Follow-Up Testing

Follow-up should address the unanswered part of the diagnostic question rather than simply repeating sequencing.

After a pathogenic result, confirmation may be unnecessary if the clinical laboratory’s method is validated and quality is high. The next priority is correlation with the phenotype, appropriate referrals, and family testing. A second method or specimen may be used when sample identity, mosaicism, or a technically complex change is in question.

After one pathogenic variant in a suspected recessive disorder, the search for a second allele may include deletion/duplication testing, genome sequencing, RNA analysis, or a specialized assay for deep intronic and structural variants. Parental samples can establish phase.

After a VUS, useful next steps may include targeted family studies, careful phenotype reassessment, functional testing, or waiting for evidence to mature. Broad medical management should not be built around an uncertain result.

After a negative result, test choice depends on why the gene was selected:

  • The phenotype remains highly specific: Review whether every relevant variant type was covered and consider a specialist laboratory or RNA-based analysis.
  • Several genes could fit: Move to a curated multigene panel.
  • The condition is complex or atypical: Consider exome or whole-genome sequencing, ideally with parental samples when appropriate.
  • A repeat disorder is possible: Order a repeat-expansion assay rather than ordinary sequencing.
  • A chromosomal disorder is possible: Use karyotype, microarray, or another structural method.
  • Mosaicism is suspected: Test an affected tissue or use a method with a lower detection threshold.

The quality of the original clinical assessment remains central. A genetics evaluation can identify features that point to a different gene, a second condition, or a nongenetic explanation. Reanalysis is especially valuable when new symptoms emerge or gene-disease knowledge changes.

Before testing, ask four practical questions: Why this gene? Which regions and variant types are covered? What will each possible result change? What is the next step if the result is negative or uncertain? Clear answers make a focused test more likely to deliver useful information and less likely to create false reassurance.

References

Disclaimer

This article is educational and does not replace evaluation by a genetics professional or other qualified clinician. The content and sensitivity of a single-gene test vary by laboratory, gene, specimen, and technology. Medical and family decisions should be based on the complete report, clinical context, and current professional guidance.

RELATED ARTICLESMORE FROM AUTHOR